For Information Contact:
VP Sales & Marketing
FOR IMMEDIATE RELEASE:
Erchonia, a Mesa-based bio-medical product company, has announced plans to build a new 15,000 square-foot facility to house their operations and accommodate increased sales. Erchonia received the first FDA approval for Low-Level Laser Therapy (LLLT). LLLT is used in pain management, physical therapy and wound healing. The company is also currently involved in a clinical trial for low-level laser assisted liposuction.
Erchonia is 85% self-reliant. They are able to perform research, development, fabrication of components and assembly of finished goods in-house. Their ability to develop specialized products from conceptual phase to market reality has helped cultivate a unique niche market.
“We’re establishing ourselves as the world leader in low level laser technology,” said Mark Shanks, Chief Financial Officer. “Our sales have increased 40% each year for the past few years.”
As part of the Business Expansion and Retention Program, the Office of Economic Development worked with Lee & Associates broker, Marc Pierce in site selection, assisted in the permitting process and will continue to work with the company as they apply for a job training grant through the Arizona Department of Commerce.
For more information on Erchonia, please visit their web site at www.erchonia.com.
Last Updated on July 18, 2017 by Erchonia